Back to discover
Disease

Dysbiosis

Late-stage therapeutic developmentExtensively researchedCooling momentum
173
Publications
18
Clinical trials
12
Related conditions
2
Related treatments
2
Related proteins
2026
Latest publication
Current focus
Alpha-synuclein biologyTherapeutic developmentInflammation & immunityMetabolic & lifestyle factorsDisease mechanisms & pathology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Gut microbiota: a promising new target in immune tolerance.

Research2025-09-18Frontiers in immunology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2028.
  • Active recent publication activity.
  • 1 industry development reported.
Research Highlights6View
Clinical Milestones3View
Industry & Market1View

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

13 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
18
All trials
5
Active
3
Late-stage
6
Completed
Recently completed

Research activity

173 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20152026
Most influential

The Microbiota-Gut-Brain Axis.

Physiological reviews · 2019 · 3,505 cites

Microbiota in health and diseases.

Signal transduction and targeted therapy · 2022 · 2,078 cites
Recent publications
Major themes8
  • Gastrointestinal Microbiome117
  • Dysbiosis39
  • Microbiota19
  • Probiotics15
  • Brain7
  • Brain-Gut Axis7
  • Alzheimer Disease6
  • Diet6
Leading journals6
  • International journal of molecular sciences19
  • Frontiers in immunology17
  • Gut microbes16
  • Nutrients15
  • Frontiers in cellular and infection microbiology10
  • Nature communications6
Leading researchers8
  • Chen X7
  • Li J5
  • Li Y5
  • Bäumler AJ4
  • Wang Y4
  • Zhang J4
  • Charitos IA3
  • Chen Y3
Affiliations (unnormalised)6
  • School of Medicine14
  • School of Pharmacy4
  • Department of Pathology and Laboratory Medicine3
  • Medical University of Lodz3
  • School of Life Sciences3
  • The First Affiliated Hospital3

Disease biology

2 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Dysbiosis is a change in the quantitative or qualitative composition of the microbiota. These shifts can disturb normal host-microbe interactions and homeostasis, and they are often linked to inflammation and disease states. The literature treats it as a microbiology and pathophysiology concept rather than a single organ-specific disease.

Causes

The supplied material supports environmental and genetic factors as contributors to microbiota perturbation. Diet is also identified as an influence on microbiota composition, and the gut-liver axis review notes dietary, genetic, and environmental inputs as relevant to microbial balance. Beyond that, the grounding does not support a more specific aetiology.

Pathophysiology

Dysbiosis reflects disruption of the normal symbiotic relationship between host and microbiota, with loss of homeostatic balance. The reviews describe downstream effects on immune regulation, colonization resistance, and host microbial interactions, with inflammation as a common consequence. In the gut-brain and gut-liver contexts, altered microbial communities can affect signaling through the immune system, tryptophan metabolism, the vagus nerve, the enteric nervous system, and microbial metabolites.

Risk factors

Environmental factors, genetic factors, and diet are supported as influences that can shift microbiota composition and increase the likelihood of dysbiosis. The literature also indicates that early-life factors can shape microbiota composition, but the supplied abstract is truncated and does not specify which factors. No additional risk factors are supported by the grounding.

Current standard of care

The grounding supports microbiota-directed approaches at the class or modality level, including probiotics and synbiotics. It also frames dysbiosis as a target for management or prevention of inflammatory and metabolic disorders, but does not provide specific treatment protocols. No other standard therapies are supported by the supplied material.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Changes in quantitative and qualitative composition of MICROBIOTA. The changes may lead to altered host microbial interaction or homeostatic imbalance that can contribute to a disease state often with inflammation.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.